REGENXBIO Inc. Files 8-K: Material Agreement
Ticker: RGNX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1590877
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
REGENXBIO inked a new deal, check the 8-K for details.
AI Summary
On January 14, 2025, REGENXBIO Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This 8-K filing indicates REGENXBIO Inc. has entered into a significant new agreement, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- 001-37553 (company) — SEC File Number
- 47-1851754 (company) — IRS Employer Identification No.
- 9804 Medical Center Drive (location) — Principal Executive Offices Address
- Rockville, Maryland (location) — Principal Executive Offices City and State
- 20850 (location) — Principal Executive Offices Zip Code
FAQ
What type of material definitive agreement did REGENXBIO Inc. enter into?
The filing states that REGENXBIO Inc. entered into a 'Material Definitive Agreement' on January 14, 2025, but the specific details of the agreement are not provided in this summary.
What is the SEC file number for REGENXBIO Inc.?
The SEC file number for REGENXBIO Inc. is 001-37553.
When is REGENXBIO Inc.'s fiscal year end?
REGENXBIO Inc.'s fiscal year ends on December 31.
What is the principal business address of REGENXBIO Inc.?
The principal business address of REGENXBIO Inc. is 9804 Medical Center Drive, Rockville, Maryland 20850.
What are the other items included in this 8-K filing?
In addition to the material definitive agreement, this 8-K filing includes Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2025-01-14 07:08:41
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
- $110 million — the Agreement, the Company will receive $110 million at closing and up to an additional $700
- $700 million — lion at closing and up to an additional $700 million if certain milestones are achieved, con
- $40 million — milestones are achieved, consisting of $40 million in potential development and regulatory
- $660 million — velopment and regulatory milestones and $660 million in potential sales milestones. The Comp
Filing Documents
- d868307d8k.htm (8-K) — 30KB
- d868307dex991.htm (EX-99.1) — 16KB
- g868307g0114004241000.jpg (GRAPHIC) — 3KB
- 0001193125-25-005659.txt ( ) — 175KB
- rgnx-20250114.xsd (EX-101.SCH) — 3KB
- rgnx-20250114_lab.xml (EX-101.LAB) — 17KB
- rgnx-20250114_pre.xml (EX-101.PRE) — 11KB
- d868307d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: January 14, 2025 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer